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Although many Trypanosoma cruzi (T. cruzi) strains isolated from a wide range of hosts have 20 
been characterized, there is a lack of information about biological features from vertically 21 
transmitted strains.  22 
We describe the molecular and biological characteristics of the T. cruzi VD strain isolated 23 
from a congenital Chagas disease patient.  24 
The VD strain was typified as DTU TcVI; in vitro sensitivity to nifurtimox (NFX) and 25 
beznidazole (BZ) were 2.88 µM and 6.19 µM respectively, while inhibitory concentrations for 26 
intracellular amastigotes were 0.24 µM for BZ, and 0.66 µM for NFX. Biological behavior of 27 
VD strain was studied in a mouse model of acute infection, resulting in high levels of 28 
parasitemia and mortality with a rapid clearence of bloodstream trypomastigotes when 29 
treated with BZ or NFX, preventing mortality and reducing parasitic load and intensity of 30 
inflammatory infiltrate in skeletal and cardiac muscle. Treatment-induced parasitological 31 
cure, evaluated after immunossupression were 41% and 35% for BZ and NFX treatment 32 
respectively, suggesting a partial response to these drugs in elimination of parasite burden.  33 
This exhaustive characterization of this T. cruzi strain provides the  basis for inclusion of this 34 
strain in a panel of reference strains for drug screening and adds a new valuable tool for the 35 
study of experimental T. cruzi infection. 36 
Keywords 37 
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1. Introduction 45 
American trypanosomiasis is an anthropozoonosis caused by the hemoprotozoa parasite T. 46 
cruzi. Also known as Chagas disease, it is endemic in Latin America, with at least 5-6 million 47 
people infected, 70 million people at risk of infection and 100,000 deaths per year [1].  48 
In endemic areas, the highest incidence of T. cruzi infection occurs in children under 10 years 49 
old [2]. Based on seroprevalence studies in pregnant women, it is estimated that nearly 50 
1,400 children are born congenitally infected each year in Argentina, where 1.6 million 51 
infected people live [1]. Remarkably, vertical transmission is currently responsible for most 52 
new cases in urban areas [3]. 53 
The life cycle of T. cruzi is complex and involves over 150 mammalian hosts and triatomine 54 
bloodsucking bugs. Transmission occurs when infected bug feces contaminate the bite site 55 
or intact mucous membranes, through blood transfusion, organ transplants, or 56 
transplacental passage. Oral infection linked to ingestion of food and/or drinks 57 
contaminated with infected triatomine feces has been also recognized as a source of 58 
outbreaks in the past few years [4].  59 
Treatment of Chagas disease currently relies on two antiparasitic drugs: benznidazole (BZ) 60 
and nifurtimox (NFX). Both compounds have an estimated efficacy of 70 and 98% in acute 61 
and congenital cases, respectively, but effectiveness decreases for patients in the chronic 62 
phase [3].  63 
Over the past few years,  a consensus was reached towards the classification of T. cruzi 64 
strains into six discrete typing units (DTUs), defined as “set of stocks that are genetically 65 
more related to each other than to any other stock and that are identifiable by common 66 
genetic, molecular, or immunological markers”, designated as Tc I to TcVI [5]. T. cruzi 67 
intraspecific genetic and phenotypic diversity was widely characterized by biological 68 
behavior, biochemical propierties and pharmacological response [6]. 69 
T. cruzi diversity can also be observed in experimental infections and treatment response. 70 
Several isolates from differente sources (humans, domestic and sylvatic animals and bugs) 71 
have been characterized in vitro and in experimental animal models, including response to 72 














studies, there is a lack of information on biological behaviour, drug sensitivity and treatment 74 
response for T. cruzi strains isolated from transplacental infection. 75 
The aim of this work was to characterize the biological and molecular properties of a T. cruzi 76 
isolate, the VD strain, obtained from a pediatric congenital case. 77 
 78 
2. Materials and Methods  79 
 80 
2.1 Clinical case 81 
 82 
A three months old baby born in a non-endemic area to a previously non treated mother 83 
with chronic indeterminate phase of Chagas disease, was referred to the Service of 84 
Parasitology and Chagas Disease, "Dr. Ricardo Gutiérrez” Children's Hospital (Buenos Aires, 85 
Argentina) with low weight, jaundice, hepatosplenomegaly and positive T. cruzi parasitemia. 86 
The child was treated initially with BZ but interrupted due to gastric intolerance; treatment 87 
was changed to NFX with good tolerance and clinical response. After treatment 88 
completition, the patient returned to his hometown and was lost to follow up. 89 
 90 
2.2 Strain isolation  91 
 92 
A blood sample from the pediatric patient was inoculated subcutaneously in 14 days old 93 
Rockland mice (n=6) (González-Cappa, SM, laboratory records). Parasites obtained from this 94 
initial isolate have been maintained by weekly passages in 21 days old CF-1 male mice, 95 
infected with 1x105 bloodstream trypomastigotes by intraperitoneal (ip) route. Bloodstream 96 
trypomastigotes are also routinely stored inliquid nitrogen. This T. cruzi isolate wil be 97 
referred  to as VD strain. For experimental purposes, VD strain bloodstream trypomastigotes 98 


















2.3 Compounds and reagents 104 
 105 
For in vitro assays, pure powder of BZ (N-Benzyl-2-nitroimidazole acetamide) (provided by 106 
Elea®, Buenos Aires, Argentina) and NFX (3-methyl-4- (5'-nitrofurfurylideneamina) 107 
tetrahydro-4H-thiazine -1,1-dioxide) (provided by Bayer®, Germany) were suspended in 108 
dimethylsulfoxide (DMSO). For in vivo assays, BZ (Abarax®, Elea) and NFX (Lampit®, Bayer) 109 
tablets were pulverized and resuspended in a 0.25% carboxymethylcellulose (CMC) solution 110 
(Sigma-Aldrich, USA).  111 
 112 
2.4 In vitro assays 113 
 114 
2.4.1 Cell culture 115 
 116 
Vero cells were grown in 25 cm2 tissue-culture flasks , using L-glutamine RPMI-1640 medium 117 
supplemented with 5% of FCS, 10 mM HEPES, 100 UI/mL penicillin and 50 µg/mL 118 
streptomycin, and incubated in 5% CO2 atmosphere at 37°C. 119 
 120 
2.4.2 Trypomastigotes drug susceptibility 121 
 122 
VD strain trypomastigotes purified from mice blood were seeded in 96-wells polystyrene flat 123 
bottom plates in 100 µL of RPMI-5% FCS (1x106 parasites/mL), exposed to five serial dilutions 124 
of NFX (100-0.3 µM) or BZ (230-0.1 µM) and incubated at 37°C in a 5% CO2–95% air mixture 125 
for 24 hours. Motile parasites were counted in a Neubauer chamber. Each drug 126 
concentration was evaluated by triplicate and compared to untreated control cultures. The 127 
50% lytic concentrations  (LC50), defined as the drug concentration that resulted in a 50% 128 
reduction of trypomastigotes viability compared to the non-treated controls, was estimated 129 

















2.4.3 Amastigote growth inhibition assay 134 
 135 
Cesium 137 irradiated Vero cells (2000 rad) were plated overnight at 37°C-5% CO2 to a 136 
density of 5x104 of cells/well, in 24-well plates with rounded coverslips at the bottom. 137 
Infection conditions were previously optimized with 2,5x105 parasites/well and incubated for 138 
3 hours at 37°C. Then,wells were washed with PBS  to remove non-attached parasites and 139 
fresh RPMI media containing NFX (20 to 0.2 µM), BZ (10 to 0.16 µM) or medium was added. 140 
Drug-contraining media was renewed every 24 hours for 3 consecutive days.; Then, cells 141 
were washed with PBS, fixed with methanol and stained with Giemsa. Each drug 142 
concentration was evaluated by triplicate. The 50% inhibitory concentration (IC50), defined 143 
as the drug concentration required to achieve 50% inhibition of intracellular amastigote 144 
growth by counting number of amastigotes per cell, was determined by non-linearregression 145 
analysis [11].  146 
 147 
2.5 In vivo assays 148 
2.5.1 Animal breeding conditions 149 
Twenty days old female BALB/c mice (15 ± 2 grams) were obtained from the Animal Facilities 150 
at the Faculty of Veterinary Sciences, University of Buenos Aires (Argentina) and maintained 151 
under conventional closed barriers at the "Dr. Ricardo Gutiérrez" Children’s Hospital Animal 152 
Facilities. Animals were housed in 600 cm2 polycarbonate at 4-5 animals per cage. Mice were 153 
individually identified and cages were properly labelled. Cages were filled with irradiated 154 
chip-bedding and changed once a week. Mice had access to food  and water ad libitum. 155 
Macroenvironmental conditions included a 12:12 hs light:dark cycle (starting at 6 a.m.), 156 



















2.5.2 Infection and treatment 163 
 164 
Mice were infected at 5 to 7 weeks of age (16.25 ± 2.09 grams) by the intraperitoneal route 165 
(ip) with 500 bloodstream VD strain trypomastigotes. Blood direct microscopic observation 166 
was performed starting at the 5th day post infection (dpi). Treatment was begun when 167 
parasites were detected in circulation; animals were then randomly assigned to the  168 
following groups: BZ (n = 17), NFX (n = 17) or infected non-treated (NT, n = 17).  169 
Treatment was administered orally for 20 consecutive days at a dose of 100 mg/kg/day for 170 
NFX or BZ, using disposable tips and an automatic pipette, in a final volume of 50 µL per 171 
animal per dose. The doses, length and route of administration were chosen based on 172 
previous published literature [12,13].  173 
Parasitemia was evaluated three times a week during therapy by pricking the tail and 174 
collecting 5 µl of fresh blood. Blood was incubated with red blood cell lysis solution (20 µl of  175 
Tris-buffered 0.83% ammonium chloride pH 7.2), and  motile parasites were counted in a 176 
Neubauer chamber. In addition, the following parasitemia parameters were recorded: 177 
prepatent period (defined as time between infection and detection of circulating parasites), 178 
patent period (time elapsed between parasitemia onset and negativization), parasitemia 179 
peak (highest parasitemia level), and number of drug doses needed to turn parasitemia 180 
undetectable. Animals were periodically weighed to adjust doses and to assess changes in 181 
body weight. Body temperature was determined rectally with a pediatric digital 182 
thermometer. Mortality was recorded daily. To avoid unnecessary pain and stress, pre-183 
established anticipated endpoints were used, and animals were euthanized if they fullfiled 184 
any of these criteria (i.e. 20% weight loss from initial body weight, body temperature lower 185 
than 33.5°C, or parasitemia higher than 2x106 trypomastigotes/mL). Euthanasia was 186 
performed with CO2 inhalation in a saturated chamber or sodium pentothal overdose (300 187 
















2.5.3 Determination of parasitological cure 191 
 192 
At the end of the treatment, 5 surviving animals from each group were euthanized, and 193 
blood and tissue samples were obtained for T. cruzi DNA detection by real-time PCR (qPCR) 194 
and histopathology. Remaining animals with undetectable parasitemia were left without 195 
treatment for 10 days, with periodic checks for re-emergence of bloodstream parasites, and 196 
then subjected to a cyclophosphamide (CYP)-based immunosuppression protocol to rule out 197 
parasite reemergence from sanctuary sites in tissues [14].  Briefly, CYP was given once a 198 
week by ip injection at 200 mg/kg for a total of 4 administrations. Animals were euthanized 199 
if parasite ressurgence was observed or, if not, after four cycles of immunosuppression, 200 
tissues (heart, skeletal muscle and brain) and blood were collected for confirmation of cure 201 
by histopathology and qPCR.  202 
 203 
2.6 Tissue sample preparation and histological evaluation 204 
 205 
Samples from  heart, skeletal muscle, brain, liver, kidney, colon and uterus were collected 206 
from all animals to evaluate inflammation and presence of amastigote nests. Samples were 207 
fixed in buffered 10% formaldehyde, dehydrated, paraffin-embedded, and 5 µm thick 208 
sections were stained with haematoxylin and eosin (H&E).  209 
Evaluation of the tissue specimens was performed by light microscopy by a researcher 210 
blinded to the treatment assignment. Presence of amastigote nests was recorded and the 211 
degree of myocardial and skeletal inflammation was scored as described previously [15,16].  212 
General histoarchitecture, inflammatory infiltrates, degree of vascular congestion and 213 
presence of amastigote nests were evaluated in liver, kidney, colon, uterus and brain. 214 
Number of inflammatory foci was determined in 100 fields at 400X magnification and extent 215 
of infiltration (expressed in µm2) was measured using Infinity Analyse program 6.5.0 216 















2.7 Quantitative PCR (qPCR) 219 
 220 
Blood samples were collected and diluted 1:3 in guanidine-EDTA buffer (GEB) (6M 221 
guanidine-HCl, 0.2M EDTA), and tissue (heart, skeletal muscle and brain) samples were 222 
rinsed with sterile distilled water and stored at -70°C until processing. DNA was extracted 223 
with High Pure PCR Template Preparation Kit (Roche®) according to the manufacturer and 224 
stored at -70°C until use. The extracted DNA was quantified by spectrophotometry at 260 225 
nm wavelength with Nanodrop 1000 (ThermoScientific®).  226 
T. cruzi DNA amplification was performed using cruzi 1 [5'-3'-ASTCGGCTGATCGTTTTCGA] and 227 
cruzi 2 [5'-3'-AATTCCTCCAAGCAGCGGATA] primers, which amplify a 166-bp specific 228 
fragment, corresponding to satellite DNA. The detection was performed using TaqMan® 229 
probe cruzi 3 [5'-3'CACACACTGGACACCAA] as previously described [17]. The standard curve 230 
allowed quantification of  DNA between a range of 1.6x 100 to 8x105 parasite 231 
equivalents/mL. An internal amplification standard (IAC) of DNA extraction (2 ng) was 232 
included in each GEB sample.  233 
 234 
2.8 Discrete Typing Unit (DTU) determination 235 
 236 
Using purified DNA from cell-culture derived trypomastigotes, the DTU of the VD strain was 237 
identified based on the molecular weight of the bands amplified by PCR targeting specific 238 
nuclear gene sequences: the intergenic region of spliced leader genes (SL-IR), the 24Sα 239 
subunit ribosomal DNA (rDNA 24sα) and the A10 fragment as previously described [18]. 240 
Amplification products were stained with Gelred® (Genbiotech SRL) and visualized in a 3% 241 


















2.9 Statistical Analysis 247 
 248 
For in vivo studies, data was subjected to analysis of variance test (ANOVA) with post-hoc 249 
correction for multiple comparisons with Bonferroni test or non-parametric Kruskal-Wallis 250 
test, and compared in pairs depending on data distribution. Survival analysis was performed 251 
using Kaplan-Meier test. In all cases, p-values<0.05 were considered statistically significant. 252 
Statistical analyses for in vivo assays were performed with InfoStat/P 2014 (Universidad 253 
Nacional de Córdoba, Argentina). BZ and NFX LC50 and IC50 were determined by non-linear 254 
regression using GraphPad Prism 5.03 software (GraphPad Software, Inc. USA).  255 
Graphics were prepared with GraphPad Prism 5.03. Values in tables and graphs are 256 
expressed in mean values with standard deviation unless otherwise indicated. 257 
 258 
2.10 Ethical statement 259 
Animals were acclimatized to new housing conditions and habituated to routine handling by 260 
trained personnel for two weeks prior to the experiment and procedures were performed 261 
according to local  guidelines [19]. Protocol was approved by the Institutional of Animal Care 262 
and Use Committee from Faculty of Veterinary – University of Buenos Aires (# Protocol: 263 
2014/4). Anticipated endpoints (see above) were impremented to avoid unnecessary 264 
suffering. 265 
 266 
3. Results 267 
 268 
3.1 Discrete Typing Unit (DTU) determination 269 
 270 
DNA analysis from cell-culture derived VD strain trypomastigotes revealed that it belongs to 271 
the DTU TcVI according to SL-PCR II 425 bp, heminested 24αS ribosomal PCR 140 bp and A10 272 
















3.2 In vitro drug sensitivity 276 
 277 
VD strain susceptibility to reference drugs (i.e. BZ and NFX) both in trypomastigotes (LC50) 278 
and intracellular amastigotes (IC50) is shown in Table 1 and dose-response curves are 279 
displayed in Supplementary Material 2 (SM2).  280 
 281 
3.3 Course of  acute infection with T. cruzi VD strain in a murine model 282 
 283 
Parasites were detected in mice blood at 8 (range 5 to 9) days post infection (dpi) (i.e. afterip 284 
innoculation), at which point they were divided into treatment (NFX or BZ) or NT groups. 285 
Mice from the NT group developed high levels of bloodstream VD trypomastigotes (Figure 286 
1A), unlike BZ or NFX groups which showed treatment response with a rapid decrease in 287 
bloodstream parasites. Parasitemia parameters are shown in Table 2. 288 
BZ and NFX were well tolerated throughout the study by all treated mice. Animals treated 289 
with BZ or NFX were clinically healthy, with shiny and well groomed fur, showing alert 290 
behavior, connected with environment. In contrast, animals in the NT group failed to recover 291 
clinically, showing a soiled and bristly coat, with hunched guarding posture and partially 292 
closed eyelids accompanied by tearing. Reduced mobility with lethargic reflexes and 293 
decreased awareness were also observed. These clinical signs were accompanied by weight 294 
loss and decreased body temperature, reaching the maximum pre-established tolerable 295 
endpoint near peak parasitemia, at approximately 21 dpi (Figure 1B). 296 
None of the animals in the NT group gained body weight during follow up, reaching weight 297 
nadir at 21 dpi. On the other hand, animals treated with BZ or NFX exhibited a less 298 
pronounced weight loss, especially in the NFX group, and a rapid weight recovery during the 299 
treatment period. Moreover, animals from the NT group exhibited lower average body 300 
temperature compared to NFX or BZ treated animals, starting from 12 dpi and reaching 301 
values closely to hypothermia at approximately 21 dpi, coinciding with peak parasitemia 302 
















3.4 Histopathological features 306 
 307 
The skeletal muscle in all studied animals in the NT group showed a high degree of 308 
rhabdomyolysis with mononuclear inflammatory infiltrates giveng a mean inflamatory score 309 
of 3.5 over 5 and muscle fiber calcifications were observed  in 4 samples. Amastigote nests 310 
could be observed in 82.35% of animals (14 / 17). By contrast, animals treated with BZ or 311 
NFX exhibited comparatively lower degrees of inflammation, with scores ranging from 0.5 to 312 
3 (over 5), and mild to moderate interfibrillar mononuclear inflammatory infiltrates without 313 
rhabdomyolysis (Figure 2A). Amastigote nests were observed in 4 of 17 samples from BZ 314 
group, whilst specimens from NFX-treated animals had no detectable  amastigote nests.  315 
Animals from the NT group also showed myocardial inflammatory foci, in some cases with 316 
local extension without involving complete heart wall (inflammation score=3) with 317 
predominantly mononuclear cells infiltrates. Inflammation scores ranged from 1 to 3 (over 318 
5). Also, 65% (11 / 17) of NT mice showed amastigote nests within cardiac fibers. BZ-treated 319 
animals showed greater variability in degree of inflammation, with scores ranging from 0 to 320 
4, with focal, but not confluent, infiltrates in the peripheral heart wall being the 321 
predominant finding. Only 29.5% (5/17) BZ-treated animals exhibited amastigote nests in 322 
myocardial samples. Mice from the NFX group showed myocardial inflammation ranging 323 
from 0 to 3 points (over 5). Similarly to BZ-treated animals, focal lesions with mononuclear 324 
infiltrates were predominant. However, amastigote nests were observed only in one animal 325 
(6%; 1 / 17). (Figure 2B) 326 
Focal mononuclear infiltrates were also the main feature in liver samples from all 327 
experimental groups. No differences were observed among groups in the number of 328 
inflammatory foci, but their sizes were larger in NT animals, followed by those treated with 329 
BZ (Figures 2C-2D). Amastigote nests were not identified in liver histological sections from 330 
any experimental group.  331 
No significant morphological and/or histological alterations, nor amastigote nests were 332 
















3.5 Assesment of treatment-induced parasitological cure  336 
 337 
After completion of 20 consecutive days of therapy with either BZ or NFX, 5 animals from 338 
each group were euthanized to obtain blood samples and target organs (skeletal muscle, 339 
heart and brain) in order to analyze parasite burden by qPCR. Table 3 shows percentage of 340 
animals with parasitic esterilization (without immunosupression) in each treatment group 341 
(i.e. BZ or NFX). Estimated parasitic loads are illustrated in Figure 3. Parasitological cure rates 342 
in BZ or NFX treated animals after inmunosuppression with CYP are shown in Table 4. 343 
In summary, adding all negative animals irrespective of whether they received 344 
immunossupression or not, the overall parasitological cure was observed in 41% (7/17) of 345 
the BZ-treated animals, and in 35% (6/17) of the NFX-treated animals. 346 
 347 
4. Discussion 348 
 349 
We have conducted the first exhaustive description of the main biological and molecular 350 
characteristics of the T. cruzi VD strain, originally isolated by our group from a congenital 351 
Chagas disease case.  352 
Based on well-established DTU methods, the VD strain belongs to DTU TcVI, supporting 353 
previous findings [20] and suggesting  genetic stability through mice passages. DTU TcVI is 354 
one of the most prevalent T. cruzi genotype in domestic trasmission cycle and it have been 355 
linked to congenital cases [18].  356 
In vitro susceptibility to BZ and NFX was assesed both in bloodstream trypomastigotes and 357 
amastigotes. Inhibitory concentration values for BZ and NFZ were similar to those reported 358 
from T. cruzi reference strains within DTU Tc VI (Tulahen and CL-Brener), but considerably 359 
below the lytic concentration from Tulahuen trypomastigotes (Table 1).  Unfurtunately, 360 
comparison with NFX in vitro sensitivity on T. cruzi trypomastigotes was hampered because 361 
most LC50 were established on epimastigote stage, which does not represent the same 362 
biological and clinical characteristics of the trypomastigote and amastigote stages, incuding 363 














Given the extreme variability in drug sensitivity even within the same DTU, there is no 365 
convincing evidence yet to support the association between in vitro sensitivity to 366 
conventional trypanocidal drugs and phylogenetic features. There are also no consistent 367 
data to support any correlation between DTU and morbidity, risk of reactivation or 368 
congenital  transmission in humans [3].  369 
While many animal models have been developed for studying Chagas disease [21], a murine 370 
model was chosen to characterize the VD strain due to the common use of this animal 371 
species for isolates maintenance, biological characterization and as suggested model for 372 
initial evaluation of tripanocidal compounds [12]. BALB/c mice strain were chosen due to 373 
their previously recognized high susceptibility to different T. cruzi isolates. Althought host 374 
variables such as age and sex may influence the course of the experimental infection [21], 375 
female mice were preferred due to easier handling and the selected age allowed induction 376 
of patent parasitemia in all animals, at a similar time (8 days post-infection) with circulating 377 
parasites counts in the same order of magnitude. However, trials with new drugs may 378 
consider evaluating efficacy in both sexes in order to improve predictability. 379 
Experimental mice infection with highly virulent T. cruzi strains (such as VD strain) produce 380 
elevated parasitemia and high mortality rates. These two effects can allow quick and easy 381 
determination of parasiticidal activity of new compounds, and make VD strain very suitable 382 
for acute infection models for drug screening [12]. The chosen inocullum was comparatively 383 
low compared to previous works [22,23], but it was based on the high virulence that VD 384 
strain exhibited. At the end of the acute phase of the infection, untreated mice mortality 385 
was near 95% in our model. These values are consistent with previous characterization of T. 386 
cruzi virulent strains [9,24]. 387 
Likewise, oral administration of BZ and NFX produced a rapid decline in parasitemia. These 388 
results illustrate an effective treatment response with conventional drugs consistent with 389 
previous descriptions [23].  390 
In our model, parasitemia reached maximum values by 18 dpi in NT animals, accompanied 391 
by symptoms compatible with systemic infection and reduced weight and body 392 
temperature. Weight loss is typical of the experimental acute phase and could be related to 393 














Histopathological findings during the acute phase of infection showed a marked tropism for 395 
skeletal and cardiac muscle. NT animals were significantly more likely to have amastigotes 396 
nests observed in these tissues than those treated with BZ and NFX, even in those who 397 
underwent immunosuppression. These results contrast with observations from models with  398 
CL-Brener or RA strains (both DTU TcVI) with a marked tissue pantropism  [25,26].  399 
Morphometric analysis of liver samples showed larger inflammatory areas in NT animals 400 
compared to those treated with conventional drugs. However, treatment with BZ and NFX 401 
was unable to decrease concomitant liver inflammation. Future studies should focus on 402 
defining whether this infiltrate is a consequence of parasite infiltration, the toxic action of 403 
nitroheterocyclic drugs or due a combined effect between T. cruzi infection and treatment, 404 
as suggested previously [27].  405 
Absence of amastigote nests in liver agrees with previous data from isolates from T. 406 
rubrovaria (DTU TcIII) in female Swiss mice [28] and might be related to the involvement of 407 
this organ as a major site of immunological elimination of parasites [29].  408 
An immunosuppression protocol with CYP and and qPCR quantification of parasite load in 409 
blood and target tissues were chosen to determine parasitological cure.  The 410 
immunosuppression protocol proved to be a good marker for treatment failure, as all 411 
animals showing parasite DNA in at least one of the analyzed tissues subsequently 412 
reactivated after administration of CYP. 413 
Importantly, none of the BZ treated animals showed persistent parasitemia by fresh blood 414 
examination after end of therapy, while only one mouse treated with NFX showed blood 415 
trypomastigotes after 20 consecutive days of treatment. Two heart and skeletal muscle 416 
samples from NFX-treated animal which did not reactivate after immunosuppresion were 417 
positive by qPCR, but due to their low parasitic load could not be quantified. Interestingly, 418 
DNA was not detectable by qPCR in blood of these mice. The presence of residual DNA in 419 
tissues or possible PCR cross contamination could explain these non quantifiable positive 420 
levels of T. cruzi DNA in tissues. Guarner et al. (2001) reported  intracellular granular 421 
antigens by immunohistochemistry, which may represent lysated parasites [31] supporting 422 
the possibility of residual DNA in tissues. Similarly, Martins et al. (2008), considered 423 














Cure rates described in the literature are very variable depending on T. cruzi strain or mouse 425 
model  as well as the particular cure criteria used in each study-  Discordant information was 426 
found in this area concerning DTU TcVI. C3H male mice infected with RA strain and treated 427 
with BZ for 20 days resulted in 50% of parasitological cure [32], while studies employing 428 
Tulahuen strain reached cure rates from none to 100% [13,33] suggesting that the 429 
correlation between DTU and drug sensitivity is not particularly strong. 430 
Similarly to our results, BZ treatment reduced the parasitemia and other associated 431 
parameters without achieving parasitological cure in any of the mice infected with isolates 432 
obtained from pediatric patients from Jequitinhonha Valley (Minas Gerais, Brazil) [23].  433 
Andrade et al. (1985) described NFX sensitivity of numerous isolates and rates of cure 434 
determined by different methods were variable. Furthermore, treatment with NFX for 10 435 
days reduced parasitemia levels below the microscopic detection limit, but failed to achieve 436 
parasitic cure assesed by qPCR in animals infected with Tulahuen or Y strains [13]. Unlike BZ, 437 
the therapeutic response and parasitological cure obtained in murine models treated with 438 
NFX have not been extensively studied. 439 
The different rates in parasitological cure obtained in experimental studies can be partly 440 
explained by the wide variety of animal models and how new biotechnological tools have 441 
modified the cure criteria. At the moment, there is no consensus on what techniques can 442 
establish unequivocally the parasitic sterilization and possibly a set of procedures 443 
(immunosuppression, qPCR, biomarkers) may provide an overall scenary to determine 444 























We have studied in depth the biological and molecular properties of the VD strain, a T. cruzi 455 
isolate obtained from a paediatric patient with congenital Chagas disease. We conclude that 456 
the VD strain can be considered one of the representative T. cruzi strain, with suitable 457 
characteristics for inclusion in a regional panel of T. cruzi reference strains for in vitro and in 458 
vivo drug screening, among other experimental uses.  459 
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Table 1. T. cruzi VD strain in vitro susceptibility to reference drugs (mean [95%confidenceinterval]) and comparison with other standard 601 
strain from same DTU. 602 
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Table 2. Parasitemia parameters evaluated in non-treated (NT), benznidazole (BZ)- or 610 
nifurtimox (NFX)-treated mice during acute phase of VD strain T. cruzi infection. Values are 611 
expressed in medians (range). 612 
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3 (3; 14)  
b 
n= 17 animals per experimental group. 613 
PPP= pre-patent period (i.e. first day of parasitemia detection). 614 
PP= patent period.  615 
1 Median (range) number of doses required to induce negative parasitemia. 616 
Values with different letters in same column are significantly different (Kruskall-Wallis; 617 





















Table 3. Parasite loads and efficacy of treatment with BZ 100 mg/kg or NFX 100 mg/kg for 20 626 
days in a murine model of acute VD strain Trypanosoma cruzi infection  without 627 









Blood Skeletal muscle Heart Brain 
Positive mice by 
any method (%) 
NT 16 / 17  17 / 17   17 / 17  17 / 17  17 / 17  17 / 17 
   (94%) (100%) (100%) (100%) (100%)  (100%) 
BZ 0 / 5  2 / 5  1 / 5   2 / 5  1 / 5   2 / 5  
   (0%) (40%)  (20%)  (40%)  (20%)  (40%) 
NFX   1 / 5  5 / 5   4 / 5  4 / 5  5 / 5   5 / 5 
   (20%)  (100%)  (80%)  (80%)  (100%)  (100%) 






























Table 4. Quantitative PCR results and efficacy of 20 days treatment with benznidazole (BZ) 647 
100 mg/kg or nifurtimox (NFX) 100 mg/kg in a murine model of acute T.cruzi VD strain 648 
















mice by any 
method (%) 
NT  1 / 1   1 / 1  1 / 1  1 / 1  1 / 1  1 / 1  1 / 1 
   (100%)  (100%)  (100%)  (100%)  (100%)  (100%)  (100%) 
BZ   8 / 12  8 / 12  8 / 12  7 / 12  7 / 12  7 / 12  8 /12 
   (67%)  (67%)  (67%)  (58%)  (58%)  (58%)  (67%) 
NFX  6 / 12  8  / 12  6  / 12 7 a / 12  8 a  / 12   6 / 12  6 / 12 
   (50%)  (67%)  (50%)  (58%)  (67%)  (50%)  (50%) 
FBE= fresh blood examination at the end of the therapy 651 
CYP= cyclophosphamide (200 mg/kg; ip). 652 


























Figure 1. A). Parasitemia curve during acute phase of infection with T. cruzi VD strain. The 666 
asterisks indicate timepoints where parasitemia levels were significantly higher in the NT 667 
group (Kruskall-Wallis; p<0,001). B). Cumulative survival curves of mice infected with T. cruzi 668 








































Figure 2. A) Inflammatory infiltrate scores in skeletal muscle. B) Inflammatory infiltrate 696 
scores in cardiac muscle. C) Liver morphometric analysis: number of inflammatory foci / 100 697 
microscope fields (x400). D)  Mean inflammatory infiltrate area in liver (expressed in µm2).  698 







































Figure 3. Estimated parasite load in T. cruzi VD strain infected, non-immunosuppressed 725 

















































































• There is lack of information on vertically transmitted T. cruzi strains.  
• T. cruzi VD strain was isolated from a congenital Chagas disease patient. 
• Main molecular and biological characteristics were described. 
• VD strain has suitable characteristics to include in a panel of reference strains. 
 
